Preexisting melanoma and hematological malignancies, prognosis, and timing to solid organ transplantation: A consensus expert opinion statement.
Preexisting melanoma and hematological malignancies, prognosis, and timing to solid organ transplantation: A consensus expert opinion statement.
复制标题
DOI：
10.1111/ajt.16324
复制
发表时间：
2021-03
期刊：
影响因子：
--
通讯作者：
Watt KD
中科院分区：
文献类型：
--
作者：
Al-Adra DP;Hammel L;Roberts J;Woodle ES;Levine D;Mandelbrot D;Verna E;Locke J;D'Cunha J;Farr M;Sawinski D;Agarwal PK;Plichta J;Pruthi S;Farr D;Carvajal R;Walker J;Zwald F;Habermann T;Gertz M;Bierman P;Dizon DS;Langstraat C;Al-Qaoud T;Eggener S;Richgels JP;Chang GJ;Geltzeiler C;Sapisochin G;Ricciardi R;Krupnick AS;Kennedy C;Mohindra N;Foley DP;Watt KD
接受实体器官移植（SOT）评估的患者通常有恶性肿瘤史。只有接受过治疗的癌症患者才考虑进行SOT，但移植的益处需要与肿瘤复发的风险相平衡，同时考虑到免疫抑制的潜在影响。先前关于既往接受过治疗的恶性肿瘤患者移植时机的指南未考虑当前分期、疾病生物学或癌症治疗进展。为了更新这些建议，美国移植学会（AST）促成了一个共识研讨会，全面审查有关癌症治疗，癌症分期特异性预后，癌症复发动力学以及免疫抑制对癌症特异性结局影响的有限数据的当代文献。本文件包含黑色素瘤和血液恶性肿瘤的预后，治疗和移植建议。鉴于有关移植受者癌症复发风险的数据有限，AST主办的会议和产生的共识文件的目标是提供专家意见建议，帮助评估有移植前恶性肿瘤病史的患者的移植候选资格。
Patients undergoing evaluation for solid organ transplantation (SOT) frequently have a history of malignancy. Only patients with treated cancer are considered for SOT but the benefits of transplantation need to be balanced against the risk of tumor recurrence, taking into consideration the potential effects of immunosuppression. Prior guidelines on timing to transplant in patients with a prior treated malignancy do not account for current staging, disease biology, or advances in cancer treatments. To update these recommendations, the American Society of Transplantation (AST) facilitated a consensus workshop to comprehensively review contemporary literature regarding cancer therapies, cancer stage specific prognosis, the kinetics of cancer recurrence, as well as the limited data on the effects of immunosuppression on cancer-specific outcomes. This document contains prognosis, treatment and transplant recommendations for melanoma and hematological malignancies. Given the limited data regarding the risk of cancer recurrence in transplant recipients, the goal of the AST-sponsored conference and the consensus documents produced are to provide expert opinion recommendations that help in the evaluation of patients with a history of a pre-transplant malignancy for transplant candidacy.
登录
查看更多内容
影响因子：
6.2
作者：
Lim, Wai H.;Turner, Robin M.;Wong, Germaine
通讯作者：
Wong, Germaine
DOI：
10.1200/edbk_201131
发表时间：
2018-05-23
期刊：
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
影响因子：
--
作者：
Eggermont, Alexander M M;Crittenden, Marka;Wargo, Jennifer
通讯作者：
Wargo, Jennifer
影响因子：
6.2
作者：
Acuna, Sergio A.;Sutradhar, Rinku;Baxter, Nancy N.
通讯作者：
Baxter, Nancy N.
DOI：
10.1016/j.jamcollsurg.2019.06.001
发表时间：
2019-12-01
影响因子：
5.2
作者：
Livingston-Rosanoff, Devon;Foley, David P.;Wilke, Lee G.
通讯作者：
Wilke, Lee G.
影响因子：
6.2
作者：
Bouvy, Anne P.;Kho, Marcia M. L.;Baan, Carla C.
通讯作者：
Baan, Carla C.